Inherited BRCA1 mutations confer elevated breast cancer risk. Recent studies have identified genes that encode proteins that interact with BRCA1 as modifiers of BRCA1-associated breast cancer. We evaluated a comprehensive set of genes that encode most known BRCA1 interactors to evaluate the role of these genes as modifiers of cancer risk. A cohort of 2,825 BRCA1 mutation carriers was used to evaluate the association of haplotypes at ATM, BRCC36, Overall, the data suggest that genomic variation at multiple loci that encode proteins that interact biologically with BRCA1 are associated with modified breast cancer and ovarian cancer risk in women who carry BRCA1 mutations.
INTRODUCTION
Inherited mutations in BRCA1 may be necessary to explain the Mendelian pattern of breast cancer in some families, but are not sufficient to completely describe inter-individual variability in age-specific cancer risk. A number of studies suggest that modifier loci influence breast cancer penetrance among BRCA1 mutation carriers. The most convincing evidence of such modifiers to date includes those genes that encode proteins that interact directly with BRCA1 or BRCA2. A recent genome-wide association study (GWAS) identified a locus on chromosome 19p13 as a modifier of breast cancer risk for BRCA1 mutation carriers(1). The most significant SNPs in this analysis were those located in a region containing three genes, among them C19ofr6, which encodes the BRCA1 interactor MERIT40, an interactor of BRCA1.
However, fine mapping has yet to be done in this region, and other loci, including ANKLE1, were also highly significantly associated with breast cancer. A RAD51 SNP has been previously shown to modify breast cancer risk for BRCA2 mutation carriers in a number of independent studies (2-4). We recently reported that variation in genes that encode BRCA1 or BRCA2 interacting proteins were associated with ovarian cancer risk, including ATM, BARD1, BRIP1, MRE11A, and RAD51 (5) . Many of these proteins have also been associated with risk of cancers and other diseases associated with DNA damage in the general population (6) (7) (8) (9) (10) . Table 1) . Because the proteins encoded by these loci are part of multi-protein complexes that interact with BRCA1 to influence DNA damage and repair pathways, these are biologically plausible modifiers of cancer risk in BRCA1 mutation carriers. Based on this knowledge, the goal of this research is to more fully explore the observation that genes encoding BRCA1-interacting proteins modify cancer risk in BRCA1 mutation carriers. Due to limited statistical power in the current data set, future studies will also include interactors of BRCA2 when sample sizes become adequate for these analyses. Author Manuscript Published OnlineFirst on July 28, 2011; DOI: 10.1158/0008-5472. information to the University of Pennsylvania, the coordinating center. The coordinating center determined eligible participants. Eligible participants included women over the age of 18, with documented disease-associated mutations in BRCA1, who had never been diagnosed with cancer at any site prior to center ascertainment. As only a small proportion of our cohort (<5%) come from minority groups, we included only participants who were white, including Hispanic, non-Hispanic, and Jewish.
The BRCA1 mutation status of all subjects was confirmed by direct mutation testing and subjects provided full informed consent for this study under protocols approved by the human subjects review boards at each institution. Some participants were simultaneously consented for both research and clinical BRCA1 testing, while others were consented separately for clinical testing and for research participation. Women with BRCA1 variants of unknown clinical significance were excluded. Mutations were included in the analysis if they were pathogenic according to generally recognized criteria, including (i) mutations generating a premature termination codon as a result of a nonsense substitution, a frameshift due to small deletion or insertion, aberrant splicing or large genomic rearrangement; (ii) mutations resulting in loss of expression due to deletion of promoter and transcription start site; (iii) large in-frame deletions spanning one or more exons caused by aberrant splicing or large genomic rearrangement and (iv) missense mutations classified as pathogenic using the algorithms of Goldgar et al (11) and Chenevix-Trench et al (12) .
Data were obtained on all eligible participants using medical records, telephone interviews, and/or self-administered questionnaires and included information on reproductive and exposure history, including hormone use and smoking. Vital status, cancer diagnoses, and prophylactic surgery data were verified by review of medical records, operative notes, and/or pathology reports if available. Time from ascertainment to cancer diagnosis or censoring was random with respect to risk-reducing salpingo-oophorectomy (RRSO), risk-reducing mastectomy (RRM), cancer occurrence, or death. In addition, because this was not a randomized clinical trial of RRSO or RRM, both the case and the control groups underwent a variety of cancer surveillance programs that were not controlled for in this study.
All participants included in this research provided informed consent for research participation under IRB-approved protocols at each of the participating center. The research presented here was also approved by the Committee on Research Involving Human Subjects at the University of Pennsylvania.
Genotype and Haplotype Data
Genomic DNA samples were extracted from peripheral blood at each center and shipped to the Penn data coordinating center. Samples were genotyped using the SNPlex TM Genotyping System (Applied Biosystems, Foster City, CA) or the OpenArray Genotyping System (Applied Biosystems, Foster City, CA) using the standard protocols. Briefly for SNPlex, 40 ng of DNA extracted from peripheral blood was fragmented using heat. Samples then underwent the Oligo Ligation Assay (OLA) where allele specific oligos (ASOs), each containing a unique identifying code (ZIPCode) were ligated to locus specific oligos (LSOs) to generate single stranded products. The products were cleaned using exonuclease to remove all unligated products. Cleaned OLA product then underwent PCR. PCR products were then bound to a plate coated with streptavidin and underwent several washes where reporters unique to each genotype (ZIP chutes) were hybridized to the products at the ZIPCode. ZIPChutes were then eluted and run on a 3130xl Capillary Sequencer. Genotypes were read using GeneMapper 4.0.
OpenArray is a small volume genotyping method based on Taqman chemistry. Genotyping by the OpenArray was done on a 64-SNP array format. Following standard protocol, samples were 
>0
.95 limited to minor allele frequencies of 5% or greater. Thirty-eight putative functional SNPs were also included if they had been reported in HapMap data or in the literature. SNPs with genotyping failure rates >20% or low minor allele frequency (MAF, <1%) were excluded from subsequent analyses. In addition, SNPs that showed significant deviations from Hardy-Weinberg equilibrium in unrelated unaffected Caucasian women were also excluded. After applying these quality control checks, we included a total of 108 SNPs in our analysis.
Statistical Analysis
Analysis was undertaken using the weighted cohort approach of Antoniou et al (13) . The weighted approach was implemented to address the issue that study carriers may be ascertained non-randomly with respect to their disease status. Mutation carriers in our study were ascertained through families that may have included multiple affected individuals who underwent BRCA1/2 mutation testing. Since the presence of disease may influence the likelihood of testing, affected carriers may be over-represented in our cohort. Under this retrospective study design, standard methods of analysis such as Cox regression can lead to biased estimates of the risk ratios. To address this potential bias, we analyzed the data within a retrospective weighted cohort framework. This approach has been shown to provide risk ratio estimates that are nearly unbiased (13) . Five-year interval weights were applied based on published breast cancer incidences for BRCA1 mutation carriers (14) .
For breast cancer analyses, women were followed from the initial time of their inclusion in the study to the earliest of the following censoring events: RRSO, RRM, death, or having reached the end of follow-up without a breast cancer or other censoring event. Time to event was computed from age at study inclusion to age at first breast cancer diagnosis or age at censoring. For ovarian cancer analyses, women were followed from the initial time of their inclusion in the study to the earliest of the following censoring events: RRSO, death, or having reached the end of follow-up without an ovarian cancer or other censoring event. For the present analyses, breast cancer diagnoses were ignored. Time to event was computed from age at study inclusion to age at first ovarian cancer diagnosis or age at censoring. Cox proportional hazards models were used to analyze the data after the proportional hazards assumption underlying the Cox model was assessed using log(-log) plots and Schoenfeld residuals test. To account for intra-cluster dependence due to multiple individuals from the same family, a robust sandwich variance estimate was used. Analyses were adjusted for ethnicity (Jewish, Hispanic, or non-Hispanic non-Jewish white) and birth cohort (decade of birth). Correction for multiple hypothesis testing was performed using the Benjamini-Hochberg method to control the false-discovery rate (FDR) (15) . All survival analyses were conducted in SAS version 9.1 (SAS Institute Inc., Cary, NC).
To investigate haplotype associations, the EM algorithm (16, 17) was used to estimate haplotype frequencies' which was implemented in R version 2.1.1 subroutine haplo.em(18). To assess the association between haplotypes and survival outcome, we created a user-defined haplotypes together with disease status) as well as haplotype-specific tests (to test the association between each haplotype and disease status) were conducted. To implement haplotype-specific survival analysis, we used the haplo.stat program, which is a set of R version 2.1.1 subroutines(18). For sparse data, haplo.stat computes simulation p-values for all tests of association. The amount of phase ambiguity was quantified by estimating the percentage of uncertainty in the imputed diplotypes. The majority of haplotypes had a maximum posterior probability of over 80%; hence we felt comfortable proceeding with the haplotype association method outlined above rather than assigning the most likely haplotype pair to each subject. As a secondary analysis, we also undertook single SNP associations using Cox proportional hazards models as implemented in SAS version 9.1 (SAS Institute Inc., Cary, NC). All p-values are based on two-sided hypothesis tests.
RESULTS
Among the cohort of 2,825 BRCA1 female mutation carriers, 1,196 (42.3%) had a breast cancer diagnosis, and 379 (13.4%) had an ovarian cancer diagnosis. As shown in Table 1 , breast and ovarian cancer cases were significantly more likely to be older at the time of study inclusion and members of an older birth cohort than controls. Controls were more likely to have undergone risk-reducing salpingo-oophorectomy (RRSO) or risk-reducing mastectomy (RRM) than breast cancer cases. Haplotype analysis was the primary approach used to identify associations. The sample sizes shown below and in the results tables vary due to sampling criteria that differ for breast and ovarian cancer analyses as well as missing genotype data for some SNPs and haplotypes.
We considered an association to be important only if we observed a statistically significant overall difference in haplotype frequencies by disease (censoring) status, and there was at least one statistically significant haplotype associated with altered breast or ovarian cancer risk. If only one of these events occurred at a particular locus, we did not consider it to demonstrate a meaningful association. All inferences are based on two-sided hypothesis tests with FDR corrected p-values to consider the number of tests conducted here.
Breast Cancer
An association was detected between breast cancer risk and haplotypes at C19orf62 (encoding MERIT40), in agreement with the prior GWAS finding at this locus(1). However, there was overlap between the samples studied here and those used in the previous GWAS publication, so this result does not represent an independent replication of that finding. Also in support of the prior GWAS, we report the association of haplotypes at this locus and breast cancer ( Table 2) . Haplotypes B and E were significantly associated with an increase in breast cancer risk with HR=1.15 and 1.22, respectively. The common SNP that is changed relative to the reference haplotype is an A>G change in SNP3 (rs3745185). One other haplotype (D) also contained this SNP and had a statistically non-significant increased HR effect, but another haplotype containing this SNP (A) did not demonstrate any increase in risk. SNP5 (rs8170) was associated with increased breast cancer risk (p=0.010, Supplementary Table 3), in agreement with the prior GWAS publication(1). Haplotype E containing allele A of this SNP (Table 3 ) was also associated with increased breast cancer risk. In addition to this previously reported association, we also identified a series of additional haplotype associations in genes encoding proteins involved in BRCA1 interactions.
As shown in Table 2 0.43-0.97). The common change in both TOPBP1 haplotypes were for SNP 1 T>C (rs3732574), but this same SNP was found in another haplotype that was not associated with increased risk. Each of the haplotypes associated with altered risk differed from the reference haplotype by multiple SNPs, so it was not possible to infer which (if any) of the individual SNPs involved in these associations was primarily (or causally) responsible for the observed associations (Supplementary Table 3 ). No significant associations were observed for BRCC36, ABRA1, MRE11A, PALB2, RAD51, or RAP80.
We also observed associations at BRCC45 in one of the six haplotype blocks considered (Table 3) , namely Haplotype G of Block 3 (HR=1.20, 95%CI: 1.03-1.41). This common haplotype with a 21% frequency differed from the reference haplotype for five of the six SNPs that comprised the haplotype (SNPs 10,11,12,13, and 15; Table 3 ). The association of haplotype B in Block 4 suggested an association, but there was no overall significant test for differences among haplotypes in this block. None of the other blocks suggested an association of this locus with breast cancer. 
Ovarian Cancer
We observed a statistically significant association of Haplotype C at ABRA1 and ovarian cancer (HR=1.42, 95%CI: 1.02-1.97; Table 4 ). This haplotype differed from the reference haplotype by only SNP1 (rs13125836). In single SNP analysis (Supplementary Table 4 Also associated with ovarian cancer risk was a single haplotype in RAP80. Carriage of haplotype G contained multiple differences from the reference haplotype, and was associated with a significantly decreased risk of ovarian cancer compared to the reference group (HR=0.69, 95%CI: 0.50-0.97; Table 4 ).
Finally, we also observed that multiple haplotype blocks in BRCC45 were associated with ovarian cancer risk ( Table 5) . Two of the six blocks (Blocks 4 and 5) showed an overall difference in haplotype frequencies by case status (as judged by the FDR-corrected p-values) and had significant individual haplotype associations. In block 4, the rare haplotype (frequency: 0.1%) was associated with an elevated risk of ovarian cancer compared to the reference haplotype in this block (HR=13.58, 95%CI: 8.83-20.89). However, this result is based on a very small number of carriers of these rare haplotypes (N=26 cases, N=162 censored individuals).
Caution must be used in interpreting this finding, and further validation will be required. In addition, haplotype D in block 5 was associated with an increase in relative risk of ovarian cancer (HR=1.45, 95%CI: 1.01-2.08). This association represents a single difference in SNP27 (rs4666053) compared to the reference haplotype. SNP27 was not associated with ovarian cancer risk in single SNP analysis (Supplementary Table 4 ).
DISCUSSION
We have identified a number of biologically plausible associations of breast or ovarian 
cancer with genes that encode proteins that are involved in DNA damage response and interaction with BRCA1. Each of these proteins interacts directly or indirectly with BRCA1
( Supplementary Figure 1) and therefore may act in concert with a mutated BRCA1 to either confer further increased cancer risk, or to mitigate the effect of the BRCA1 mutation to lessen breast cancer risk. These results are therefore both biologically plausible and support earlier studies where individual genes of interest in these pathways have been reported as cancer risk genotypes.
The list of potential modifier gene associations reported here does not include those that were previously reported by our group (e.g., BRCA1/2 interacting proteins in ovarian cancer (5)) or others (e.g., RAD51 in BRCA2-associated breast cancer(19)). However, in combination with our present results, the literature now provides strong evidence that interactors of BRCA1 and BRCA2 are breast and ovarian cancer risk modifiers in women who have inherited a diseaseassociated BRCA1 or BRCA2 mutation. As shown in Table 6 , there is now evidence for genetic variability in ATM, BRCC45, BRIP1, CTIP, MERIT40, NBS1, RAD50, and TOPBP1 in BRCA1-associated breast cancer; BARD1 and RAD51 in BRCA2-associated breast cancer; ATM, BRCC45 and RAP80 in BRCA1-associated ovarian cancer; and ATM, BARD1, BRIP1, MRE11, and RAD51 in BRCA2-associated ovarian cancer. Therefore, there is strong evidence that genetic variation associated with proteins involved in BRCA1-associated multiprotein complexes contribute to breast and ovarian carcinogenesis.
A number of these associations have been reliably repeated in studies using a variety of approaches. We report here using a candidate haplotype association approach that MERIT40 is associated with BRCA1-associated breast cancer risk. In the prior GWAS, haplotype analysis included 6 SNPs (rs4808611, rs3745185, rs8170, rs4808075, rs100241, and rs2363956). Two of these SNPs were also included in the present analysis (rs3745185, denoted SNP3 here; and Table 2 ). The inferred risk haplotypes from the GWAS study were those that included the G allele at rs3745185. This is the same change found in the putative risk haplotype reported here (Haplotypes B and E, Table 2 ). Therefore, both studies have reported the same alleles (haplotypes) are associated with breast cancer risk in BRCA1 mutation carriers. MERIT40 is a component of the BRCA1 complex that also includes ABRA1 (FAM175A), BARD1, RAP80, BRCC36 and BRCC45 (Supplementary Table 1 ).
In the present study, we also found BRCC45 to be an additional modifier of BRCA1-associated breast cancer risk. However, in a separate study, we found no association of BARD1
Cys557Ser or haplotypes and breast cancer risk(20). This complex is required for recruitment
and retention of the BRCA1-BARD1 ubiquitin ligase and the BRCC36 deubiquitination enzyme at sites of DNA damage(21, 22). Thus, genetic variants that modify MERIT40 or BRCC45 function or expression might influence BRCA1-dependent DNA repair and checkpoint activity in BRCA1 mutation carriers sufficiently to increase the risk of breast cancer.
We also expanded this result by identifying additional associations with genes encoding proteins involved in other BRCA1-associated complexes (Supplementary Figure 1 and Supplementary Table 1) . We found associations with CTIP, NBS1, and RAD50, suggesting that mutations in genes responsible for regulation of CHK1 activation leading to homologous recombination also influence BRCA1-associated breast cancer risk. We also found associations with BRIP1 and TOPBP1, both of which interact with BRCA1 to regulate S-Phase and G2 cell cycle arrest and influence homologous recombination. Note that BRIP1 also interacts with BRCA2 in regulation of related pathways. We have previously reported that BRIP1 is also associated with ovarian cancer risk in BRCA2 mutation carriers.
In contrast, we found no associations with RAD51 or PALB2. RAD51 interacts with ovarian(5) cancer risk in BRCA2 mutation carriers but not in BRCA1 mutation carriers in most studies (Table 6 ). These results suggest that modifiers of BRCA1-or BRCA2-associated breast or ovarian cancer risk are more likely to involve those proteins that directly interact with either BRCA1 or BRCA2, rather than those that are indirectly associated with BRCA1 or BRCA2.
Strengths of this study include a relatively large cohort of BRCA1 mutation carriers and a focus on biologically plausible associations involving genes that encode proteins that interact with BRCA1. A limitation of this study is that the sample size remains insufficient to detect some small effects. For example, some analyses involve a relatively small number of ovarian cancer cases, and the effects found for rare haplotypes depend only on a small number of observations. As a result, we have in some cases detected relatively large HR effects that were not statistically significant. We did not have the power to study interactions or higher-order effects among genes or with exposures. Therefore, additional large-scale studies should be undertaken to confirm the results reported here. Finally, new BRCA1/2 interactors are being discovered and the evaluation of all of the genes that encode BRCA1/2 interactors remains incomplete (Table 6 ). Thus, additional research is required to completely assess these genes as risk modifiers.
Despite the biological plausibility of our results, we cannot make strong inferences about the mechanism of these associations. The SNPs selected here were chosen to optimally reflect haplotypes at these loci, but these haplotypes themselves may not be functionally relevant. We single SNP analyses, then we may infer that the observed effect represents one or more variants that lie on that haplotype, but may or may not have been measured here. If the observed effect is less for haplotypes than single SNP results, but the risk estimate across all haplotypes that share that allele are similar or in the same direction, then the allele itself may be of interest. As an example of the limitations of our approach in making causative or mechanistic inferences, we observed statistically significant effects in opposite directions for BRIP1 variants in breast vs. ovarian cancer among mutation carriers. While the usual hypothesis to be made is that the effect of modifiers may be in the same direction for cancers at different sites, the effects of modifier genes may be tissue specific, or have other functional consequences that vary by tumor site that the present analyses cannot address. These results again argue in favor of subsequent functional or mechanistic studies to elucidate the fundamental causes of our statistical associations. Finally, despite the relatively large sample sizes available to this study, we do not have sufficient statistical power to attempt analyses of interactions among loci. This research may provide important insights into the joint effects of multiple loci in this pathway in future analyses when even larger sample sets are available.
Taken together, these results provide strong evidence that genes encoding proteins that interact directly with BRCA1 are modifiers of BRCA1-associated breast cancer risk. These associations may be valuable in a number of ways. First, these associations may be used to identify a set of modifiers to assist in risk assessment of BRCA1/2-associated cancers. Second, these associations may provide additional information about the biological relationships of the multiprotein complexes associated with BRCA1 and/or BRCA2 and expand the list of therapeutic targets. 
